Medical treatment composition comprising mammalian dental pulp stem cells

• US 10,328,103 B2
• Filed: 03/15/2013
• Issued: 06/25/2019
• Est. Priority Date: 01/03/2009
• Status: Active Grant

• Current Assignee: Ray C. Wasielewski
• Original Assignee: Ray C. Wasielewski
• Inventors: Wasielewski, Ray C.
• Primary Examiner(s): Moloye, Titilayo
• Application Number:
  US13/835,568
• Publication Number:
  US 20130309208A1
• Time in Patent Office: 2,293 Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/42 Phosphorus; Compounds thereof
• CPC Class Codes: A61K 35/32 Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 38/20 Interleukins [IL]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2400/06 Flowable or injectable implant compositions
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells

Abstract

A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Pluripotent stem cells, other cells, and biologic constituents of the dental pulp may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the pluripotent stem cells, other cells, and biologic constituents of the dental pulp can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair.

Claims

1. A medical treatment composition comprising:

a dental pulp suspension including viable mammalian dental pulp stem cells, mammalian dental pulp proteins, and extracellular matrix proteins, wherein the suspension has not been digested by collagenase and the stem cells have not been cultured; and

a non-naturally occurring cryoprotectant, the cryoprotectant being dimethyl sulfoxide;

wherein the composition is in a form that is safe for injection into pathologic or injured tissue.

2. The composition of claim 1, wherein the extracellular matrix proteins are derived from mammalian dental pulp.

3. The composition of claim 2, wherein the mammalian dental pulp is equine dental pulp.

4. The composition of claim 3, wherein the equine dental pulp is chosen from neonatal equine dental pulp and fetal equine dental pulp.

5. The composition of claim 3, wherein the equine dental pulp is taken from the premolar or molar teeth of the mandibular and maxillary regions.

6. The composition of claim 2, wherein the mammalian dental pulp has been physically disrupted, without isolation of stem cells, to prepare the suspension.

7. The composition of claim 1, wherein the suspension is chosen from a single cell suspension and a multiple cell suspension.

8. The composition of claim 1 wherein the mammalian dental pulp stem cells are chosen from pluripotent mammalian dental pulp stem cells, multipotent mammalian dental pulp stem cells, and mixtures thereof.

9. The composition of claim 1, wherein the suspension further comprises one or more growth factors.

10. The composition of claim 9, wherein the one or more growth factors are chosen from transforming growth factor beta, insulin like growth factor I, insulin like growth factor II, platelet-derived growth factor, fibroblast growth factor, and bone morphogenetic proteins.

11. The composition of claim 1, wherein the suspension further includes cells that, in combination with the mammalian dental pulp stem cells, provide a population of cells in the suspension that, in the aggregate, are CD34 positive, CD44 positive, CD45 positive, CD90 positive, and CD105 positive.

12. The composition of claim 1, wherein the suspension further includes hard components of a tooth.

13. The composition of claim 12, wherein the hard components of the tooth are chosen from dentin and enamel.

14. The composition of claim 12, wherein the hard components of the tooth have been processed into a particulate, ground, or powder form.

15. The composition of claim 1, wherein the suspension further includes hydroxyapatite.

16. The composition of claim 1, wherein the mammalian dental pulp proteins or extracellular matrix proteins include at least one protein chosen from an anti-inflammatory protein, an anti-degradative protein, interleukin-1 receptor antagonist, collagen type I, and glycosaminoglycans.

17. The composition of claim 1, wherein the suspension includes a vehicle for the mammalian dental pulp stem cells, mammalian dental pulp proteins, and extracellular matrix proteins, the vehicle comprising a balanced salt and glucose solution.

18. The composition of claim 1, wherein the mammalian dental pulp stem cells and mammalian dental pulp proteins are derived from an equine source.

19. A medical treatment composition comprising:

a dental pulp that has been filtered to provide a particulate form including viable mammalian dental pulp stem cells, mammalian dental pulp proteins, and extracellular matrix proteins; and

a non-naturally occurring cryoprotectant;

wherein the composition is in a form that is suitable for injection into pathologic or injured tissue.

20. A medical treatment composition comprising:

a mechanically disrupted dental pulp suspension including viable mammalian dental pulp stem cells, mammalian dental pulp proteins, and extracellular matrix proteins, wherein the mechanically disrupted dental pulp is achieved by grinding dental pulp; and

a non-naturally occurring cryoprotectant;

wherein the composition is in a form that is safe for injection into pathologic or injured tissue.